GLP 1, Tirzepatide and Retatrutide: Where Weight Loss Medicine Is Going Next
Weight loss medicine has changed dramatically in just a few years.
First came the explosion of GLP 1 treatments.
Then tirzepatide pushed results further.
Now retatrutide is producing Phase 3 numbers that would have seemed extraordinary not long ago.
But for anyone interested in body composition and performance, the most important question is not simply how much weight these drugs can remove.
It is what happens to the body while that weight comes off.
GLP 1 Changed the Conversation
GLP 1 treatments changed weight management because they made appetite regulation a much more powerful clinical tool.
Semaglutide became the name most people recognised.
But the significance was bigger than one medication.
It demonstrated that obesity could increasingly be treated through biological appetite regulation rather than relying entirely on willpower and restriction.
That changed expectations around what medical weight management could achieve.
And then tirzepatide moved the benchmark again.
Tirzepatide: From One Pathway to Two
Tirzepatide works differently from traditional GLP 1 treatments because it acts on both GIP and GLP 1 receptors.
You do not need to understand the biology to understand the practical consequence.
The clinical results have been substantial.
In the SURMOUNT 1 trial, participants receiving tirzepatide achieved average weight reductions of up to 20.9 percent over 72 weeks.
More recently, the SURMOUNT 5 trial directly compared tirzepatide with semaglutide in adults with obesity without diabetes.
Tirzepatide produced greater reductions in both body weight and waist circumference. (nejm.org)
This is no longer an experimental discussion.
Tirzepatide is an established medical treatment.
But what is coming next is even more interesting.
Retatrutide: The Triple Agonist
Retatrutide adds another pathway.
It targets GIP, GLP 1 and glucagon receptors.
Again, the mechanism is less important for most people than what is happening in the clinical trials.
In May 2026, Eli Lilly reported results from the Phase 3 TRIUMPH 1 trial.
Participants receiving the highest studied dose lost an average of 28.3 percent of their body weight over 80 weeks.
Among participants who started with a BMI of at least 35 and continued in an extension to 104 weeks, average weight reduction reached 30.3 percent. (investor.lilly.com)
Additional Phase 3 results announced in July showed average reductions of up to 20.8 percent in people with type 2 diabetes and obesity or overweight, and up to 22.6 percent in people with more severe obesity and established cardiovascular disease. (investor.lilly.com)
These are impressive numbers.
But there is an important distinction.
As of September 2026, retatrutide remains investigational.
It is not an approved weight loss medication.
Lilly currently plans to submit it to the FDA in the first quarter of 2027.
And the recent Phase 3 percentages above come from company reported topline results rather than fully published peer reviewed trial papers.
That context matters.
The Evolution Is Becoming Clear
The progression is relatively easy to understand.
Semaglutide
GLP 1
Established weight management treatment.
Tirzepatide
GIP plus GLP 1
Established treatment with greater average weight reduction than semaglutide in a direct clinical trial.
Retatrutide
GIP plus GLP 1 plus glucagon
Investigational treatment with highly significant Phase 3 weight loss results.
More pathways do not automatically mean a better treatment for every individual.
But the direction of research is clear.
Weight management drugs are becoming increasingly sophisticated and increasingly powerful.
The Next Shift Is Not Only About More Weight Loss
There is another change happening at the same time.
The treatment experience itself is becoming simpler.
In June 2026, the UK authorised an oral semaglutide tablet for weight management. (gov.uk)
Then in August, the UK became the first country in Europe to authorise orforglipron for weight management and type 2 diabetes.
Unlike semaglutide and tirzepatide, orforglipron is not a peptide and is taken orally. (gov.uk)
This matters because the next generation of obesity treatment may not simply be about producing greater weight reduction.
It may also be about making treatment easier to access, easier to administer and easier to integrate into normal life.
Weight Loss Is Not the Same as Body Transformation
This is the part I think deserves much more attention.
A scale measures total weight.
It does not tell you what you have lost.
Fat mass matters.
But so does lean mass.
Muscle.
Strength.
Function.
Performance.
A 2026 analysis of randomised trials found that lean mass represented a meaningful proportion of total weight lost during incretin based treatment.
The same analysis found that combining lifestyle intervention with resistance training produced a more favourable lean mass profile than weight loss interventions without it. (pubmed.ncbi.nlm.nih.gov)
That does not mean GLP 1 therapies are damaging muscle.
Significant weight loss naturally includes some lean tissue.
The better question is:
How good is the quality of the weight loss?
For someone focused on performance and body composition, losing 20 kilograms while becoming weaker, undernourished and physically inactive is not the same result as losing substantial fat while maintaining strength and muscle.
That is why training becomes more important, not less.
Protein becomes more important.
Recovery becomes more important.
And body composition becomes more useful than simply watching the scales.
Powerful Tools Still Need a Strategy
I do not personally use GLP 1 medication or peptides.
And I have been transforming bodies for years without relying on them.
But pretending these treatments are not changing weight management would make no sense.
They clearly are.
The mistake is thinking the medication becomes the entire strategy.
Whether someone loses weight naturally or receives appropriate medical treatment, my objective remains the same.
Preserve muscle.
Build strength.
Improve body composition.
Create habits that can survive beyond the weight loss phase.
And build a body that performs better, not simply one that weighs less.
That is the foundation of my Online Coaching.
If you want a personalised training, nutrition and lifestyle strategy built around your body and your goals, you can explore my Online Coaching and build the foundations that matter regardless of which additional tools you choose to use.
This article is for educational purposes only and does not constitute medical advice. Prescription weight management medications should be discussed with an appropriately qualified healthcare professional.
If you want a personalised plan built around your body, your schedule and your goals, you can explore my Online Coaching and start with a structured approach that works with or without additional tools.
Comments